Tenderwize
Wróć do wyszukiwania

Non-exclusive pharmaceutical discount agreement under Open-House model for Oralair(R) (ATC V01AA02)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Aug 31, 2028 · 739 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

20/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

20 / 100

Złożoność

30 / 100

Czynniki ryzyka

The buyer reserves the right to terminate the Open-House process early if exclusive discount agreements are concluded...

No minimum purchase volumes; actual demand depends on patient numbers, prescription behavior, and pharmacy stocking. Re...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Aug 2028
  • Non-exclusive discount agreements for Oralair(R) (ATC V01AA02) under § 130a Abs. 8 SGB V
  • Supply of pharmaceutical product including parallel and re-imports
Pokaż pełne podsumowanie

This is a non-exclusive pharmaceutical discount agreement under an Open-House model for the drug Oralair(R) (ATC V01AA02), organized by AOK PLUS for Saxony and Thuringia. The agreement is not a formal public procurement but a voluntary transparency notice. Any qualified pharmaceutical entrepreneur can join by submitting participation documents via the DTVP portal. The first submission deadline is August 5, 2026, with periodic deadlines thereafter. The agreement ends on August 31, 2028. No estimated value, guaranteed volumes, or award criteria are provided. The process is open but subject to confidentiality and early termination if exclusive agreements are concluded.

Ryzyka

The buyer reserves the right to terminate the Open-House process early if exclusive discount agreements are concluded...

No minimum purchase volumes; actual demand depends on patient numbers, prescription behavior, and pharmacy stocking. Re...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG

Eligibility

  • Must submit declaration of no exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen)

Administrative

  • Must submit Russia sanctions declaration (Eigenerklärung Russlandsanktionen)

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive pharmaceutical discount agreement under Open-House model for Oralair(R) (ATC V01AA02)

This lot covers the conclusion of non-exclusive discount agreements for the pharmaceutical product Oralair(R) (ATC V01AA02), including parallel and re-imports. The contract is under an Open-House model, with rolling submission deadlines. The agreement ends on August 31, 2028. No minimum volume or exclusivity is guaranteed.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Aug 2026 - Aug 2028

Kategoria

Pharmaceutical products

Termin

Deadline Aug 31, 2028

Szczegóły zamówienia

Data publikacji
09 Jul 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
477144-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-07 - Follitropin delta

Aug 30